597 related articles for article (PubMed ID: 32670285)
1. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
[TBL] [Abstract][Full Text] [Related]
3. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
4. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
Zhang AH; Skupsky J; Scott DW
Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
[TBL] [Abstract][Full Text] [Related]
5. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
6. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
[TBL] [Abstract][Full Text] [Related]
7. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
8. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
Samelson-Jones BJ; Arruda VR
Front Immunol; 2020; 11():618. PubMed ID: 32425925
[TBL] [Abstract][Full Text] [Related]
9. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
10. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.
Adair P; Su Y; Scott DW
Discov Med; 2013 May; 15(84):275-82. PubMed ID: 23725600
[TBL] [Abstract][Full Text] [Related]
11. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
12. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
[TBL] [Abstract][Full Text] [Related]
14. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
Blood; 2017 Dec; 130(23):2559-2568. PubMed ID: 28978569
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
[TBL] [Abstract][Full Text] [Related]
18. Escape or Fight: Inhibitors in Hemophilia A.
Merlin S; Follenzi A
Front Immunol; 2020; 11():476. PubMed ID: 32265927
[TBL] [Abstract][Full Text] [Related]
19. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.
Werwitzke S; Vollack N; von Hornung M; Kalippke K; Kutzschbach J; Trummer A; Ganser A; Tiede A
Thromb Haemost; 2015 Nov; 114(6):1127-35. PubMed ID: 26245154
[TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]